CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 24 target
Drug / intervention
Disitamab vedotindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05940896
NCT05940896Phase 1RecruitingUpdate OverdueUpdated 31mo ago · Completion was 19mo ago
Enrollment Stalled
Long Recruiting
Update Overdue
CompareCT.gov

Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of Disitamab Vedotin Intravenously Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression Phase 1 Study

RemeGen Co., Ltd.·interventional·Posted Jul 11, 2023·Updated Nov 27, 2023

In Brief

A Phase 1 clinical trial evaluating Disitamab vedotin for Solid Tumor. Currently recruiting, targeting 24 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

To evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of Disitamab Vedotin(DV, RC48-ADC) intravenously combined with radiotherapy in the treatment of locally advanced solid tumors with HER2 expression

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
2024202520262027
First PostedJul 11, 2023
Enrollment StartJun 29, 2023
Primary CompletionNov 16, 2024
Study CompletionFeb 28, 2027
TodayJul 1, 2026
Enrollment to primary: 1.4 yearsPosted 3.0 years ago

Interventions

Disitamab vedotindrug

Disitamab Vedotin intravenously combined with radiotherapy (concurrent)